OBJECTIVE: To examine the role of matrix metalloproteinase 9 (MMP-9) in migraine during headache and asymptomatic periods. METHODS: Thirty-four patients with migraine with and without aura (according to International Headache Society criteria) were studied. Clinical characteristic of headache were recorded. Blood samples for measurement of MMP-9 were drawn during headache attacks and during asymptomatic periods in all patients and in 10 healthy controls. RESULTS: We found higher plasma MMP-9 levels in migraine patients than in control group (129.3 [78.0-258.9] vs. 49.6 [39.1-64.3] ng/mL; P < .001). Migrainous patients showed higher MMP-9 plasma levels during headache attacks than in asymptomatic periods, both in migraine without aura (338.4 [275.1-396.2] vs. 118.2 [75.3-137.5] ng/mL; P < .0001), and migraine with aura (389.3 [273.4-487.1] vs. 139.3 [107.3-191.4] ng/mL; P < .0001). CONCLUSIONS: Our study showed an increased production of MMP-9 during migraine attacks. These data suggest a possible role of inflammation or blood-brain barrier disruption during the migraine attack.
OBJECTIVE: To examine the role of matrix metalloproteinase 9 (MMP-9) in migraine during headache and asymptomatic periods. METHODS: Thirty-four patients with migraine with and without aura (according to International Headache Society criteria) were studied. Clinical characteristic of headache were recorded. Blood samples for measurement of MMP-9 were drawn during headache attacks and during asymptomatic periods in all patients and in 10 healthy controls. RESULTS: We found higher plasma MMP-9 levels in migrainepatients than in control group (129.3 [78.0-258.9] vs. 49.6 [39.1-64.3] ng/mL; P < .001). Migrainouspatients showed higher MMP-9 plasma levels during headache attacks than in asymptomatic periods, both in migraine without aura (338.4 [275.1-396.2] vs. 118.2 [75.3-137.5] ng/mL; P < .0001), and migraine with aura (389.3 [273.4-487.1] vs. 139.3 [107.3-191.4] ng/mL; P < .0001). CONCLUSIONS: Our study showed an increased production of MMP-9 during migraine attacks. These data suggest a possible role of inflammation or blood-brain barrier disruption during the migraine attack.
Authors: Joseph Prandota; Anna Gryglas; Aleksander Fuglewicz; Agata Zesławska-Faleńczyk; Barbara Ujma-Czapska; Leszek Szenborn; Janusz Mierzwa Journal: World J Clin Pediatr Date: 2014-08-08
Authors: Yago Leira; Pablo Ameijeira; Clara Domínguez; Esteban López-Arias; Paulo Ávila-Gómez; María Pérez-Mato; Tomás Sobrino; Francisco Campos; Francesco D'Aiuto; Rogelio Leira; Juan Blanco Journal: Clin Oral Investig Date: 2019-05-20 Impact factor: 3.573
Authors: Elisa Rubino; I Rainero; G Vaula; F Crasto; E Gravante; E Negro; F Brega; S Gallone; L Pinessi Journal: J Headache Pain Date: 2009-02-10 Impact factor: 7.277